Log in

Start Your Membership Now

March 17, 2011 On March 17, 2011 members of the Illinois Mental Health Summit sent a letter of concern to the Illinois State Department of Healthcare and Family Services over a change in the open access policy for Medicaid recipients that made only two non-generic atypical antipsychotic medications – Zyprexa and Geodon – available to Medicaid recipients on the Preferred Drug List (PDL). All other medications are subject to prior approval (PA) with only a limited exception for persons who are currently receiving these medications. The letter lays out their argument for the impact of restrictions to access to psychotropic drugs . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Market Intelligence Resource | March 17, 2011

Mental Health Summit Letter re: Restrictions On Access To Psychotropic Medications For Medicaid Recipients In Illinois

March 17, 2011 On March 17, 2011 members of the Illinois Mental Health Summit sent a letter of concern to the Illinois State Department of Healthcare and Family Services over a change in the open access policy for Medicaid recipients that made only two non-generic atypical antipsychotic medications – Zyprexa and Geodon – available to Medicaid recipients on the Preferred Drug List (PDL). All other medications are subject to prior approval (PA) with only a limited exception for persons who are currently receiving these medications. The letter lays out their argument for the impact of restrictions to access to psychotropic drugs . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.